{"id":4144,"date":"2021-05-06T05:40:00","date_gmt":"2021-05-06T05:40:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-q1-2021\/"},"modified":"2021-05-06T05:40:00","modified_gmt":"2021-05-06T05:40:00","slug":"delarsrapport-q1-2021","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/delarsrapport-q1-2021\/","title":{"rendered":"Del\u00e5rsrapport Q1 2021"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>&#034;Utvecklingen av Nanexa forts\u00e4tter och i b\u00f6rjan av kvartalet startade vi v\u00e5rt andra egna produktprojekt, NEX-20. Valet av multipelt myelom som v\u00e5r andra indikation passar bra tillsammans med myelodysplastiskt syndrom (MDS) i NEX-18 och skapar en intressant portf\u00f6lj inom hematologisk cancer. Under 2021 har vi f\u00f6r avsikt att identifiera ytterligare ett projekt, NEX-21, d\u00e4r PharmaShell\u00ae kan skapa ytterligare en unik produkt med stor potential.&#034; David Westberg, vd Nanexa AB.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>V\u00e4sentliga h\u00e4ndelser under f\u00f6rsta kvartalet<\/strong><\/p>\n<ul>\n<li>Applied Ventures investerade 1 miljon dollar i en riktad emission i enlighet med det investeringsavtal som ing\u00e5tts i slutet av 2020, vilket tillf\u00f6rde bolaget omkring 8 miljoner kronor efter emissionskostnader.<\/li>\n<\/ul>\n<ul>\n<li>Nanexa beslutade att bolagets andra egna produktprojekt, NEX-20, inriktas p\u00e5 att utveckla en l\u00e5ngtidsverkande formulering av lenalidomid f\u00f6r behandling av multipelt myelom.<\/li>\n<\/ul>\n<ul>\n<li>Nanexa tecknade ett utv\u00e4rderingsavtal med ett icke namngivet europeiskt biotechbolag. F\u00f6retaget driver ett utvecklingsprojekt inom hj\u00e4rt-\/k\u00e4rlomr\u00e5det d\u00e4r PharmaShell\u00ae kan m\u00f6jligg\u00f6ra en l\u00e5ngverkande injicerbar produkt.<\/li>\n<\/ul>\n<ul>\n<li>Inl\u00f6sen av teckningsoptioner av serie TO2 genomf\u00f6rdes under perioden 1-15 februari 2021 med en teckningsgrad om 97,5 procent, vilket tillf\u00f6rde bolaget 24,9 miljoner kronor f\u00f6re emissionskostnader. Antalet aktier och r\u00f6ster i bolaget \u00f6kade d\u00e4rmed med 2 956 588 till 24 866 934 aktier och r\u00f6ster.<\/li>\n<\/ul>\n<ul>\n<li>Jonas Fransson rekryterades som chef f\u00f6r farmaceutisk utveckling och kommer att ing\u00e5 i Nanexas ledningsgrupp fr\u00e5n och med den 1 maj 2021.<\/li>\n<\/ul>\n<p><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong><\/p>\n<ul>\n<li>Applied Ventures investerade ytterligare 0,5 miljoner dollar genom nyttjande av teckningsoptioner som emitterats i samband med den riktade emissionen under Q1 2021. Nanexa tillf\u00f6rdes genom emissionen 4,3 miljoner kronor f\u00f6re emissionskostnader och antalet aktier och r\u00f6ster i bolaget \u00f6kade d\u00e4rmed med 480 879 till 25 347 813 aktier och r\u00f6ster.<\/li>\n<\/ul>\n<ul>\n<li>Nanexa startade sin f\u00f6rsta kliniska studie i april 2021. Det \u00e4r en fas I-studie i NEX-18-projektet som g\u00f6rs f\u00f6r att studera farmakokinetik, s\u00e4kerhet och tolerabilitet.<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 januari \u2013 31 mars 2021<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 536 (1 192) kSEK<\/li>\n<\/ul>\n<ul>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -6 623 (-3 469) kSEK<\/li>\n<\/ul>\n<ul>\n<li>Resultatet efter skatt uppgick till: -6 670 (-3 525) kSEK<\/li>\n<\/ul>\n<ul>\n<li>Resultat per aktie uppgick till: -0,29 (-0,22) SEK<\/li>\n<\/ul>\n<ul>\n<li>Periodens kassafl\u00f6de uppgick till: 22 158 (32 672) kSEK<\/li>\n<\/ul>\n<ul>\n<li>Likvida medel vid periodens utg\u00e5ng: 34 849 (44 050) kSEK<\/li>\n<\/ul>\n<p><em>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><br \/>\u00a0\u00a0<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag fokuserat p\u00e5 utvecklingen av PharmaShell\u00ae, ett nytt och banbrytande drug delivery-system med stor\u00a0potential inom ett flertal substanstyper och indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae utvecklar Nanexa egna projekt och har samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland\u00a0AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/2f79befe-ec0c-428e-8c19-4cff37fae037\/delarsrapport-q1-2021.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Del\u00e5rsrapport Q1 2021<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8221;Utvecklingen av Nanexa forts\u00e4tter och i b\u00f6rjan av kvartalet startade vi v\u00e5rt andra egna produktprojekt, NEX-20. Valet av multipelt myelom som v\u00e5r andra indikation passar bra tillsammans med myelodysplastiskt syndrom (MDS) i NEX-18 och skapar en intressant portf\u00f6lj inom hematologisk cancer. Under 2021 har vi f\u00f6r avsikt att identifiera ytterligare ett projekt, NEX-21, d\u00e4r PharmaShell\u00ae kan skapa ytterligare en unik produkt med stor potential.&#8221; David Westberg, vd Nanexa AB.<\/p>\n","protected":false},"template":"","class_list":["post-4144","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q1_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Del\u00e5rsrapport Q1 2021 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/delarsrapport-q1-2021\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Del\u00e5rsrapport Q1 2021 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"&quot;Utvecklingen av Nanexa forts\u00e4tter och i b\u00f6rjan av kvartalet startade vi v\u00e5rt andra egna produktprojekt, NEX-20. Valet av multipelt myelom som v\u00e5r andra indikation passar bra tillsammans med myelodysplastiskt syndrom (MDS) i NEX-18 och skapar en intressant portf\u00f6lj inom hematologisk cancer. Under 2021 har vi f\u00f6r avsikt att identifiera ytterligare ett projekt, NEX-21, d\u00e4r PharmaShell\u00ae kan skapa ytterligare en unik produkt med stor potential.&quot; David Westberg, vd Nanexa AB.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/delarsrapport-q1-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/delarsrapport-q1-2021\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/delarsrapport-q1-2021\\\/\",\"name\":\"Del\u00e5rsrapport Q1 2021 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2021-05-06T05:40:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/delarsrapport-q1-2021\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/delarsrapport-q1-2021\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/delarsrapport-q1-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Del\u00e5rsrapport Q1 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Del\u00e5rsrapport Q1 2021 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-q1-2021\/","og_locale":"sv_SE","og_type":"article","og_title":"Del\u00e5rsrapport Q1 2021 - Nanexa AB","og_description":"\"Utvecklingen av Nanexa forts\u00e4tter och i b\u00f6rjan av kvartalet startade vi v\u00e5rt andra egna produktprojekt, NEX-20. Valet av multipelt myelom som v\u00e5r andra indikation passar bra tillsammans med myelodysplastiskt syndrom (MDS) i NEX-18 och skapar en intressant portf\u00f6lj inom hematologisk cancer. Under 2021 har vi f\u00f6r avsikt att identifiera ytterligare ett projekt, NEX-21, d\u00e4r PharmaShell\u00ae kan skapa ytterligare en unik produkt med stor potential.\" David Westberg, vd Nanexa AB.","og_url":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-q1-2021\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-q1-2021\/","url":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-q1-2021\/","name":"Del\u00e5rsrapport Q1 2021 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2021-05-06T05:40:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-q1-2021\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/delarsrapport-q1-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/delarsrapport-q1-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Del\u00e5rsrapport Q1 2021"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/4144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=4144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}